Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Biospace med To Accelerate Market Expansion Of EOS In North America, Europe

Biospace med has raised $18m to accelerate market expansion in North America (NA) and Europe of the company’s FDA-cleared EOS ultra-low-dose 2D/3D imaging system for bones.

Biospace med said that the EOS is a new medical imaging technique that allows full-body 2D and 3D imaging of patients using radiation doses up to 89% lower than those required for a standard CR (computed radiography) X-ray. EOS will reduce irradiation linked to radiological investigations, which has risen by 600% over the past 20 years.

The benefits of EOS are particularly important in pediatrics, because children undergo X-rays throughout their development, when their organs are highly susceptible to ionizing radiation. EOS is also beneficial in adults who do not wish to be exposed to ionizing radiation during standard X-rays or CT scans.

EOS targets particularly the diagnosis, follow-up, preoperative assessment and postoperative follow-up of degenerative diseases and bone and joint deformities. Indeed, EOS allows full-body and three-dimensional (3D) images of the human skeleton with the help of the software that reconstructs and models a patient’s bones from just two simultaneous images.

The software also generates 3D measurements (lengths, angles) automatically, and can calculate a broad range of clinical parameters, some of which were hitherto inaccessible, but which are essential to diagnosis and surgical planning. The images and clinical parameters are obtained in standing or seated weight-bearing positions and thus reflect the bone and joint status of the patient’s posture.

Marie Meynadier, CEO of biospace med, said: “We are particularly pleased to welcome CDC Entreprises as a new shareholder in the company, and to acknowledge the renewed confidence of our current shareholders. This new fund raising will allow us to accelerate the market penetration of EOS in North America and Europe, so that this revolutionary musculoskeletal imaging modality can become a routine clinical tool.”